摘要
目的:比较利培酮与氯丙嗪治疗精神分裂症的疗效及安全性。方法:将120例符合CCMD-3诊断标准的男性精神分裂症患者随机分为两组,分别给予利培酮和氯丙嗪治疗8周,以阳性症状与阴性症状量表(PANSS)进行疗效评定,以不良反应症状量表(TESS)评定不良反应。结果:两组PANSS总分及各因子分治疗后均有明显下降。利培酮组有效率90.0%,氯丙嗪组有效率为85.0%,两组疗效差异无显著性。利培酮组的不良反应较氯丙嗪组少,其中,锥体外系和抗胆碱能的不良反应发生率显著少于氯丙嗪组。结论:利培酮和氯丙嗪治疗精神分裂症疗效基本相同,但利培酮的不良反应发生率明显低于氯丙嗪组。
Objective：To research the efficacy and safety of risperidone and chlorpromazine in the treatment of schizophrenic patients. Methods： 120 male patients with schizophrenia by CCMD - 3 were randomly allocated to two groups treated with risperidone or chlorpromazine for 8 weeks. The Positive and Negative Syndrome Scale （PANSS） and Treatment Emergent Side effect Scale （TESS） were used to evaluate efficacy and adverse effect respectively. Results： The total scores of PANSS and the scores of every factors were significantly decreased. The efficacy rates of risperidone and chlorpromazine were 90.0% and 85.0%, without any significantly difference between two groups. Side effects in the risperidone group were fewer than in the chlorpromazine group, and especially the rates of extrapyramidal and anticholinergic side effects were lower. Conclusion： Risperidone has a similar total efficacy compared with chlorpromazine, but has fewer side effects.
出处
《中国民康医学》
2009年第20期2492-2493,共2页
Medical Journal of Chinese People’s Health
关键词
男性
精神分裂症
利培酮
氯丙嗪
Men
Schizophrenia
Risperidone
Chlorpromazine
